| MDL | - |
|---|---|
| Molecular Weight | 661.08 |
| Molecular Formula | C28H27ClF2N8O5S |
| SMILES | O=S(C1=CC=C(N[C@H](C2=NC=CC=C2Cl)C3=C4OC(F)(F)OC4=CC=C3)C(NC5=NC(OC)=NC(N6CCNCC6)=N5)=C1)(C)=O |
|
DOT1L 0.11 nM (IC 50 ) |
Dot1L-IN-4 (Compound 10) is tested in cellular assays to assess the ability to inhibit the dimethylation of H3K79 in HeLa cells (ED 50 H3K79me2 Elisa =1.7 nM) and HOXA9 gene expression in Molm-13 cells (ED 50 HOXA9 RGA =33 nM). Dot1L-IN-4 also inhibits mixed lineage leukemia (MLL) with an IC 50 of 99 µM [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Dot1L-IN-4 (Compound 10; 300 mg/kg; p.o.; qd) is not tolerated at such a high dose by tumor xenograft bearing mice, and at a 6-fold reduced dose, the tumor growth as well as the HOXA9 reporter gene mRNA are reduced only by less than half as compared to control animals [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Male mice (C57BL/6) bearing subcutaneous MV4-11 tumor xenografts [1] |
| Dosage: | 300 mg/kg (Pharmacokinetic Analysis) |
| Administration: | P.o. |
| Result: | Was not tolerated at such a high dose by tumor xenograft bearing mice, and at a 6-fold reduced dose, the tumor growth as well as the HOXA9 reporter gene mRNA were reduced only by less than half as compared to control animals. |
Solid
Room temperature in continental US; may vary elsewhere.
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
DMSO : ≥ 220 mg/mL ( 332.79 mM )
* "≥" means soluble, but saturation unknown.
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.5127 mL | 7.5634 mL | 15.1268 mL |
| 5 mM | 0.3025 mL | 1.5127 mL | 3.0254 mL |
| 10 mM | 0.1513 mL | 0.7563 mL | 1.5127 mL |